Ethical Concerns about Psilocybin Intellectual Property

Introduction

In 1957 R. Gordon Wasson's widely read Life Magazine article brought the Mazatec mushroom ceremonies to international attention, after which chemist Albert Hofmann and Sandoz isolated and synthesised psilocin and psilocybin and patented extraction and therapeutic methods. Gerber and colleagues situate these events as the origin of a long trajectory in which Western pharmaceutical actors have developed and commercialised psilocybin-based products, while the Mazatec people who preserved the sacred mushroom traditions have received no recognised benefit. The authors note the contemporary commercial stakes—depression affects an estimated 264 million people worldwide and represents a market worth hundreds of billions of dollars in the United States—while contrasting a neoliberal framing of psilocybin as a valuable commodity with an indigenous framing that emphasises stewardship, spirituality and cultural continuity. This paper examines ethical concerns about intellectual property and bioprospecting around psilocybin, focusing on the historical case of the Mazatec and the broader legal and policy context. Gerber and colleagues review international instruments and conventions relevant to indigenous rights and traditional knowledge, outline patterns of extraction and appropriation in psilocybin research and development, and highlight the absence of reciprocal agreements or reparative measures despite at least 24 registered patent processes related to psilocybin. The authors present a normative argument that current intellectual property practices risk perpetuating colonial harms and call for frameworks that protect indigenous intangible cultural heritage and ensure fair benefit sharing. The extracted text contains no empirical methods or original data collection; it functions as an ethical and legal analysis and commentary.